Description A medication used to control blood sugar in type 1 and type 2 diabetes, typically in combination with mealtime insulin.
DrugBank ID DB01278
Modality Small Molecule
Patents 4
Indicated Conditions 2
Pramlintide is an amylin analog used for the management of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
Symlin
Generic Name Pramlintide
DrugBank Accession Number DB01278
Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Groups Approved, Investigational
Weight Average: 3949.44
Monoisotopic: 3946.920675009
Chemical Formula C 171 H 267 N 51 O 53 S 2
For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
Pramlintide is a synthetic analog of amylin, a glucoregulatory hormone that is synthesized by pancreatic β-cells and released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. It is provided as an acetate salt. Pramlintide is a 37-amino acid polypeptide that differs structurally from human
